Irena Nalepa

Prof. Dr. Irena Nalepa

Department of Brain Biochemistry, Maj Institute of Pharmacology of the Polish Academy of Sciences, Smętna 12, 31-343 Krakow, Poland
orcid

Research Focus & Metrics

Academic Career Length

50Years (1977-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2000 in European Journal of Pharmacology
Verified
Journal Article
Closed access
JVJerzy Vetulani
Jerzy Vetulani
Irena NalepaIrena Nalepa
Irena Nalepa

24 June 2021 in Frontiers in Cellular Neuroscience
Verified
Journal Article
Open access
MJMonika Jankowska-Kieltyka
Monika Jankowska-Kieltyka
ARAdam Roman
Adam Roman
Irena NalepaIrena Nalepa
Irena Nalepa
Air pollution is regarded as an important risk factor for many diseases that affect a large proportion of the human population. To date, accumulating reports have noted that particulate matter (PM) is closely associated with the course of cardiopulmonary disorders. As the incidence of Alzheimer’s disease (AD), Parkinson’s disease (PD), and autoimmune disorders have risen and as the world’s population is aging, there is an increasing interest in environmental health hazards, mainly air pollution, which has been slightly overlooked as one of many plausible detrimental stimuli contributing to neurodegenerative disease onset and progression. Epidemiological studies have indicated a noticeable association between exposure to PM and neurotoxicity, which has been gradually confirmed by in vivo and in vitro studies. After entering the body directly through the olfactory epithelium or indirectly by passing through the respiratory system into the circulatory system, air pollutants are subsequently able to reach the brain. Among the potential mechanisms underlying particle-induced detrimental effects in the periphery and the central nervous system (CNS), increased oxidative stress, inflammation, mitochondrial dysfunction, microglial activation, disturbance of protein homeostasis, and ultimately, neuronal death are often postulated and concomitantly coincide with the main pathomechanisms of neurodegenerative processes. Other complementary mechanisms by which PM could mediate neurotoxicity and contribute to neurodegeneration remain unconfirmed. Furthermore, the question of how strong and proven air pollutants are as substantial adverse factors for neurodegenerative disease etiologies remains unsolved. This review highlights research advances regarding the issue of PM with an emphasis on neurodegeneration markers, symptoms, and mechanisms by which air pollutants could mediate damage in the CNS. Poor air quality and insufficient knowledge regarding its toxicity justify conducting scientific investigations to understand the biological impact of PM in the context of various types of neurodegeneration.

1 September 2013 in Journal of Neuroimmunology
Verified
Journal Article
Closed access
MZMagdalena Zychowska
Magdalena Zychowska
EREwelina Rojewska
Ewelina Rojewska
GKGrzegorz Kreiner
Grzegorz Kreiner
Irena NalepaIrena Nalepa
Irena Nalepa
BPBarbara Przewlocka
Barbara Przewlocka
JMJoanna Mika
Joanna Mika

12 March 2018 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
EREwelina Rojewska
Ewelina Rojewska
MZMagdalena Zychowska
Magdalena Zychowska
APAnna Piotrowska
Anna Piotrowska
GKGrzegorz Kreiner
Grzegorz Kreiner
Irena NalepaIrena Nalepa
Irena Nalepa
JMJoanna Mika
Joanna Mika
Current investigations underline the important roles of C–C motif ligands in the development of neuropathic pain; however, their participation in diabetic neuropathy is still undefined. Therefore, the goal of our study was to evaluate the participation of macrophage inflammatory protein-1 (MIP-1) family members (CCL3, CCL4, CCL9) in a streptozotocin (STZ)-induced mouse model of diabetic neuropathic pain. Single intrathecal administration of each MIP-1 member (10, 100, or 500 ng/5 μl) in naïve mice evoked hypersensitivity to mechanical (von Frey test) and thermal (cold plate test) stimuli. Concomitantly, protein analysis has shown that, 7 days following STZ injection, the levels of CCL3 and CCL9 (but not CCL4) are increased in the lumbar spinal cord. Performed additionally, immunofluorescence staining undoubtedly revealed that CCL3, CCL9, and their receptors (CCR1 and CCR5) are expressed predominantly by neurons. In vitro studies provided evidence that the observed expression of CCL3 and CCL9 may be partially of glial origin; however, this observation was only partially possible to confirm by immunohistochemical study. Single intrathecal administration of CCL3 or CCL9 neutralizing antibody (2 and 4 μg/5 μl) delayed neuropathic pain symptoms as measured at day 7 following STZ administration. Single intrathecal injection of a CCR1 antagonist (J113863; 15 and 20 μg/5 μl) also attenuated pain-related behavior as evaluated at day 7 after STZ. Both neutralizing antibodies, as well as the CCR1 antagonist, enhanced the effectiveness of morphine in STZ-induced diabetic neuropathy. These findings highlight the important roles of CCL3 and CCL9 in the pathology of diabetic neuropathic pain and suggest that they play pivotal roles in opioid analgesia.

1 September 2014 in European Neuropsychopharmacology
Verified
Journal Article
Closed access
ABAgnieszka Basta-Kaim
Agnieszka Basta-Kaim
ESEwa Szczesny
Ewa Szczesny
KGKatarzyna Głombik
Katarzyna Głombik
Katarzyna StachowiczKatarzyna Stachowicz
Katarzyna Stachowicz
JSJoanna Slusarczyk
Joanna Slusarczyk
WLWładysław Lasoń
Władysław Lasoń

1 February 2018 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
PZPaweł Zajdel
Paweł Zajdel
TKTomasz Kos
Tomasz Kos
Krzysztof MarciniecKrzysztof Marciniec
Krzysztof Marciniec
GSGrzegorz Satała
Grzegorz Satała
VCVittorio Canale
Vittorio Canale
PPPiotr Popik
Piotr Popik